Key result
Cardiac myosin inhibitors and septal ablation offer effective alternatives to surgical myectomy in hypertrophic cardiomyopathy.
Why the study?
Despite substantial advances in hypertrophic cardiomyopathy management, advanced heart failure remains a major cause of morbidity.
A comprehensive, individualized approach utilizing novel pharmacotherapies and septal reduction therapies is required for optimal management of symptomatic hypertrophic obstructive cardiomyopathy.
Despite substantial advances in the management of hypertrophic cardiomyopathy, advanced heart failure remains a major cause of morbidity in this patient population. This narrative review presents the case of a patient with hypertrophic obstructive cardiomyopathy who underwent alcohol septal ablation to frame a discussion of modern therapies for hypertrophic cardiomyopathy. The current treatment landscape includes medications, both old and new, and surgical and procedural interventions to relieve mechanical obstruction. Several promising new modalities for relieving obstruction are in the nascent stages of development.
No takes yet. Share an insight, caveat, or question.
Doliner et al. (2024) conducted a review in Hypertrophic obstructive cardiomyopathy (HOCM) (n=1). Alcohol septal ablation and modern medical therapies was evaluated. Although surgical myectomy remains the gold standard, alcohol septal ablation and emerging pharmacotherapies like cardiac myosin inhibitors provide effective, tailored options for relieving mechanical obstruction in hypertrophic cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: